58-14-0

Basic information

• Product Name: Pyrimethamine
• Synonyms: 2,4-Diamino-5-(4-chlorophenyl)-6-ethylpyrimidine;2,4-Diamino-5-chlorophenyl-6-ethylpyrimidine;2,4-Pyrimidinediamine, 5-(4-chlorophenyl)-6-ethyl-;2,4-Pyrimidinediamine, 5-(p-chlorophenyl)-6-ethyl-;2,4-Pyrimidinediamine,5-(4-chlorophenyl)-6-ethyl-;4753 R.P.;4753r.p.;5-(4’-chlorophenyl)-2,4-diamino-6-ethylpyrimidine
• CAS NO: 58-14-0
• Molecular Formula: C₁₂H₁₃ClN₄
• Molecular Weight: 248.71
• EINECS: 200-364-2
• Product Categories: APIs & Intermediate;Pyrimidine;Organics;Amines;Bases & Related Reagents;Heterocycles;Intermediates & Fine Chemicals;Nucleotides;Pharmaceuticals;Inhibitor;Heterocycle-Pyrimidine series;DARAPRIM
• Mol File: 58-14-0.mol

Chemical Properties

• Melting Point: 233-234°C
• Boiling Point: 393.35°C (rough estimate)
• Flash Point: 251 °C
• Appearance: white solid
• Density: 1.2171 (rough estimate)
• Vapor Pressure: 8.34E-10mmHg at 25°C
• Refractive Index: 1.6110 (estimate)
• Storage Temp.: 0-6°C
• Solubility: Prepare the solution immediately before use. Dissolve 0.25 g in a mixture of 1 volume of methanol R and 3 volumes of methylene chloride R and dilute to 10 mL with the same mixture of solvents. The solution is clear (2.2.1) and not more intensely coloured than reference solution BY6 (2.2.2, Method II).
• PKA: pKa 7(t=20.0) (Uncertain)
• Water Solubility: <0.01 g/100 mL at 21℃
• Stability: Stable, but light sensitive. Combustible. Incompatible with strong oxidizing agents.
• Merck: 14,7985
• BRN: 219864
• CAS DataBase Reference: Pyrimethamine(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrimethamine(58-14-0)
• EPA Substance Registry System: Pyrimethamine(58-14-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36
• Safety Statements: 26
• RIDADR: 3249
• WGK Germany: 3
• RTECS: UV8140000
• HazardClass: 6.1(b)
• PackingGroup: III
• Hazardous Substances Data: 58-14-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Pyrimethamine is used as an antimalarial agent for the treatment of malaria caused by plasmodia P. vivax, P. malariae, P. ovale, including P. falciparum. It exhibits antimicrobial action against the causative agents of malaria and possesses sporontocide action.
Used in Preventing Malaria:
Pyrimethamine is used for preventing malaria in areas where the Plasmodium species are non-resistant to pyrimethamine. It is often used in combination with sulfadoxine under the brand name Fansidar, which contains a pyrimethamine-sulfadoxine ratio of 1:20.
Used in Treating Toxoplasmosis:
Pyrimethamine is used in combination with a sulfonamide for the treatment of Toxoplasmosis. A combination of pyrimethamine, sulfonamide, and quinine is the drug of choice for acute attacks of malaria and its chloroquine-resistant forms. Pyrimethamine in combination with sulfadiazine or trisulfapyrimidine is also the drug of choice for toxoplasmosis, with the combined drug being known as Daraprim.
Used in Combination Therapy:
Pyrimethamine is generally used in combination with other antimicrobial agents due to its synergistic activities, similar to those of trimethoprim/sulfonamide combinations. This helps in enhancing the treatment and prophylaxis of chloroquine-resistant falciparum malaria and prevents the development of resistance.
Chemical Properties:
Pyrimethamine is a white solid with the chemical definition of ChEBI: An aminopyrimidine that is pyrimidine-2,4-diamine, which is substituted at position 5 by a p-chlorophenyl group and at position 6 by an ethyl group.
Brand Name:
The brand name for pyrimethamine is Daraprim, manufactured by GlaxoSmithKline.

Pharmacology and mechanism of action

Pyrimethamine is a diaminopyrimidine which is structurally related to trimethoprim. It is effective against erythrocytic stage of Plasmodium (P) falciparum and less so against P. vivax, P. ovale and P. malariae. Pyrimethamine also inhibits the sporogony in the mosquito, resulting in a decrease of transmission of the infection within the community [1]. The mechanism of action of pyrimethamine is related to its inhibition of dihydrofolic reductase necessary for the folic acid synthesis in the parasite. Pyrimethamine acts slowly and is not recommended as monotherapy for acute malaria attacks. Resistance to pyrimethamine developed soon when the drug was used on a large scale as monoprophylaxis [1]. In resistant strains, the enzyme dihydrofolic reductase binds to pyrimethamine several hundred times less than in sensitive strains [2]. This high grade resistance is probably a onestep mutation and cannot be overcome by increasing the dose. However, when combined with long-acting sulphonomides (sulphadoxine), the effect of pyrimethamine is potentiated and the risk of developing resistant strains is far less.

Preparations

Pyrimethamine combined with sulphadoxine. ? ? Fansidar? (Roche). Tablets (pyrimethamine 25 mg plus sulphadoxine 500 mg). Solution for intramuscular injection (pyrimethamine 10 mg/ml and sulphadoxine 200 mg/ml).

Antiprotozoal veterinary drug

Pyrimethamine is a widely used broad-spectrum antiprotozoal veterinary medicine. In addition to this, pyrimethamine can also be applied to the breeding of the aquatic product and is also capable of enhancing the disease resistance capability of aquaculture fish. However, pyrimethamine has significant side effects with being used in excess amount being able to cause damage to the reproductive system of livestock and poultry, and is also difficult for recovery. Pyrimethamine has inhibitory effect on the primary exo-erythrocytic stage of Plasmodium falciparum and vivax malaria, and is a good preventive medicine. Although it has no significant effects on the malaria gametocyte but when the drug-containing blood enters into the mosquito body, it can affect the development of gametocytes inside mosquitoes, thus being able to interrupt the transmission. The mechanism of action is to inhibit the dihydrofolate reductase and affect the utilization of folate, causing reduction of the nucleic acid synthesis and inhibiting the malaria parasite reproduction. Meanwhile pyrimethamine and chloroquine, through lowering the level of oxidative stress and apoptosis, can exert protective effect on the placental pathology after the infection of malaria and can also reduce the proportion of infected red cells in the blood, therefore being able to achieving a excellent therapeutic effect on malaria. It also has enrichment effect in aquatic body. Upon going beyond a certain range, it can cause hemolytic anemia after being eaten and even has direct toxicity on the central nervous system. This product is mainly used for the prevention of malaria and can also be used for the treatment of toxoplasmosis. It has inhibitory effects on the primary exo-erythrocytic stage of some kinds of Plasmodium falciparum and vivax malaria and is a good preventive medicine. Owing to its slow excretion rate, it has a long-lasting effect with the preventive effect of one-time medication being able to be maintained for more than 1 week. Although this product has no significant effects on the malaria gametocyte but when the drug-containing blood is inhaled into the mosquito body, it can affect the development of gametocytes inside mosquitoes, thus being able to interrupt the transmission. Because of its effect on inhibiting the exo-erythrocytic stage of Plasmodium, it is usually used in combination with primaquine for the prevention of recurrence. This product appears as white crystalline powder; it is odorless and tasteless. It is insoluble in water, slightly soluble in ethanol, chloroform and acetone and soluble in dilute acid. It has a melting point of 232~235 ℃. Figure 1 is a structural formula of pyrimethamine

Role and purpose

This product can inhibit dihydrofolate reductase, causing failure of the conversion from dihydrofolate into tetrahydrofolate, resulting in decreased synthesis of nucleic acid, so that the parasite propagation is inhibited. It is mainly used for the prevention of malaria, it can also be combined with primaquine to prevent relapse of malaria.

Pharmacokinetics

After oral administration, gastrointestinal absorption is complete but very slow with the blood concentration reaching peak after four hours. Plasma protein has a binding rate of 80%. It is mainly distributed in tissues such as liver, lung, kidney and other tissues as well as in milk. The half-life is about 90 hours with only 10% to 20% of the prototype drug being excreted through the urine at 5 to 7 days after administration. The effective concentration of the blood can be maintained for two weeks. Therefore, single-time medication can has its preventive effect be maintained for more than 1 week.

Side effects

1. Upon administration of high dose can cause acute poisoning symptoms such as fatigue, nausea, vomiting, abdominal pain, fever, cyanosis, jaundice, splenomegaly, etc. Upon this condition, drug administration should be promptly discontinued and the patients should be subject to gastric lavage, rehydration and symptomatic treatment. Because of the sweet taste of this product, it is more prone for children to be subject to mistakenly administration and poisoning, special attention should be paid. 2. Long-term administration can interfere with the in vivo utilization of folic acid, producing megaloblastic anemia. Therefore, the patients should be subject to regularly monitoring of blood. If the above issue happens, we should treat with leucovorin.

Side effects

Relatively few side effects are associated with the usual antimalarial dosages. However, signs of toxicity are evident at higher dosages, particularly those used in the management of toxoplasmosis. Many of these reactions reflect the interference of pyrimethamine with host folic acid metabolism, especially that occurring in rapidly dividing cells. Toxic symptoms include anorexia, vomiting, anemia, leukopenia, thrombocytopenia, and atrophic glossitis. CNS stimulation, including convulsions, may follow an acute overdose.The side effects associated with the pyrimethamine–sulfadoxine combination include those associated with the sulfonamide and pyrimethamine alone. In addition, there is evidence of a greater incidence of allergic reactions, particularly toxic epidermal necrolysis and Stevens-Johnson syndrome, with the combination. This carries an estimated mortality of 1:11,000 to 1:25,000 when used as a chemoprophylactic.

Precautions

1. Lactating women and patients of renal dysfunction should take with caution. Pregnant women in early phase should be disabled. Children less than 1 year of age should not use. 2. This product has slightly fragrance without bitter taste and should be protected from the reach of children whose mistaken administration can lead to poisoning, convulsions (Children under age 6 who takes 50~100mg can get poisoning and die). Barbiturates can confront its role in the central excitability. 3. This product, after single-time overdose of long-term continuous administration can cause bone marrow suppression and gastrointestinal function inhibition, resulting in megaloblastic anemia and leukopenia with timely withdrawal leading to self-healing. Giving formylation CF may alleviate the bone marrow function. 4. Adults, after single dose administration of 150~200mg have the risk of poisoning. It often occurs of nausea, vomiting, headache, dizziness and other symptoms within 1 to 5 hours with convulsions and coma occurring in severe cases. Children under 6 years of age can die upon administration at draught of 50~100mg and get poisoning and die, it should be given attention. First aid measures: apply gastric lavage, vomiting; drink a lot of sugar or 10% carrot juice. The patients can further subject to administration of the glucose infusion and diuretics. Patients of spasms and convulsions should be subject to infusion of thiopental. 5. Patients of renal damage, unconsciousness, 6-GPD deficiency and giant cell anemia should take with caution. This information is edited by Xiongfeng Dai from lookchem.

Medicine interactions

Being used in combination with dihydrofolate synthetase inhibitors (such as sulfadoxine or dapsone) can double block the folate metabolism of malaria parasite and enhance its performance, delay or prevent the emergence of drug-resistant strains of insects. It can’t be used in combination with other kinds of dihydrofolate reductase inhibitor because it can enhance the toxicity.

Dosage

Prophylaxis: start administration at 1 to 2 weeks before entering into the affected area. It is generally recommended to keep administration to until 6 to 8 weeks after leaving the affected areas once per week and 25 mg per time. Children take once per week with 0.9 mg/kg per time with the highest dose limited for adults. For Plasmodium falciparum caused chloroquine-resistant strains: take 50 mg daily with 2 times. For children, take 0.3 mg/kg at 3 times per day with the course of three days. Toxoplasmosis: Daily 50~100 mg, administrate at draught at a dose of 25 mg after 1 to 3 days with a course of 4 to 6 weeks. For children, take 1 mg/kg with 2 times. After 1-3 days, change to 0.5 mg/kg daily at 2 times with a course of 4 to 6 weeks.

References

1. Black RH, Canfield CJ, Clyde DF, Peters W, Wernsdorfer WH (1986). Chemotherapy of Malaria, 2nd edn, edited by L.J.Bruce-Chwatt. (Geneva: World Health Organization), pp. 77–80. 2. The biology of malaria parasites. Technical Report Series no 743 (1987). (Geneva: World Health Organization). 3. Friman G, Nystr?m-Rosander C, Jonsell G, Bj?rkman A, Svendsrup B (1985). Agranulocytosis associated with malaria prophylaxis with Maloprim. BMJ, 286, 1244–1245. 4. Pyrimethamine. Therapeutic Drugs, edited by Sir Colin Dollery (1991), (London: Churchill Livingstone), pp. P314–P317.

Indications

Pyrimethamine (Daraprim) is the best of a number of 2,4- diaminopyrimidines that were synthesized as potential antimalarial and antibacterial compounds. Trimethoprim (Proloprim) is a closely related compound. Pyrimethamine is well absorbed after oral administration, with peak plasma levels occurring within 3 to 7 hours. An initial loading dose to saturate nonspecific binding sites is not required, as it is with chloroquine. However, the drug binds to tissues, and therefore, its rate of renal excretion is slow. Pyrimethamine has a half-life of about 4 days. Although the drug does undergo some metabolic alterations, the metabolites formed have not been totally identified.

Air & Water Reactions

Pyrimethamine is a diaminopyrimidine which is structurally related to trimethoprim. It is effective against erythrocytic stage of Plasmodium (P) falciparum and less so against P. vivax, P. ovale and P. malariae. Pyrimethamine also inhibits the sporogony in the mosquito, resulting in a decrease of transmission of the infection within the community[1]. The mechanism of action of pyrimethamine is related to its inhibition of dihydrofolic reductase necessary for the folic acid synthesis in the parasite. Pyrimethamine acts slowly and is not recommended as monotherapy for acute malaria attacks. Resistance to pyrimethamine developed soon when the drug was used on a large scale as monoprophylaxis [1]. In resistant strains, the enzyme dihydrofolic reductase binds to pyrimethamine several hundred times less than in sensitive strains [2]. This high grade resistance is probably a onestep mutation and cannot be overcome by increasing the dose. However, when combined with long-acting sulphonomides (sulphadoxine), the effect of pyrimethamine is potentiated and the risk of developing resistant strains is far less.

Reactivity Profile

Pyrimethamine together with sulphadoxine (Fansidar) is used in the treatment of P. falciparum malaria (cf. Sulphadoxine: Indications). Pyrimethamine is also valuable in the treatment of toxoplasmosis.

Fire Hazard

Pyrimethamine in combination with sulphadoxine (Fansidar) can cause severe cutaneous adverse reactions (cf. Sulphadoxine: Side effects). Agranulocytosis occurs quite frequently (1/2000) and fatalities have been reported when pyrimethamine is combined with dapsone [3]. When given alone, life-threatening adverse reactions are very rare and the drug is generally well tolerated. Megaloblastic anaemia may, however, occur during long-term treatment with high doses (i.e. for toxoplasmosis) and can be prevented by folinic acid supplementation [4].

Biological Activity

During long-term treatment with high doses, folinic acid supplement is usually given.

Mechanism of action

The combination of pyrimethamine with a long-acting sulfonamide, sulfadoxine, which blocks dihydrofolate synthesis by blocking incorporation of PABA into the dihydrofolate, is called Fansidar, which produces sequential blockage of tetrahydrofolate synthesis similar to that reported for treatment of bacterial infections. Plasmodium enzymes catalyzing folic acid synthesis differ from those enzymes found in other organisms. A single bifunctional protein present in Plasmodium sp. catalyzes the phosphorylation of 6-hydroxymethyl-7,8-hydropterin (a pyrophosphokinase) and the incorporation of PABA into dihydropteroic acid. A second bifunctional enzyme catalyzes the reduction of dihydropteroic acid and thymidylic acid synthesis. As a result, the drug combination (Fansidar) appears to have improved drug-mediated disruption of folic acid in Plasmodium sp.. This combination has been used with quinine for the treatment and prevention of chloroquine-resistant malaria (Plasmodium falciparum, Plasmodium ovale, Plasmodium vivax, and Plasmodium malaria). The combination therapy (Fansidar) has the added advantage of being inexpensive, which is essential for successful therapy in developing countries. When used on its own, pyrimethamine is a blood schizonticide without effects on the tissue stage of the disease.

Clinical Use

Pyrimethamine has been recommended for prophylactic use against all susceptible strains of plasmodia; however, it should not be used as the sole therapeutic agent for treating acute malarial attacks. As mentioned previously, sulfonamides should always be coadministered with pyrimethamine (or trimethoprim), since the combined antimalarial activity of the two drugs is significantly greater than when either drug is used alone. Also, resistance develops more slowly when they are used in combination. Sulfonamides exert little or no effect on the blood stages of P. vivax, and resistance to the dihydrofolate reductase inhibitors is widespread. In addition to its antimalarial effects, pyrimethamine is indicated (in combination with a sulfonamide) for the treatment of toxoplasmosis.The dosage required is 10 to 20 times higher than that employed in malarial infections.

Safety Profile

Poison by ingestion, subcutaneous, and intraperitoneal routes. Experimental teratogenic and reproductive effects. Questionable carcinogen. Human mutation data reported. When heated to decomposition it emits very toxic fumes of Cland NOx. Used as an antimalarial drug for humans and to treat toxoplasmosis in hogs.

Synthesis

Pyrimethamine, 2,4-diamino-5-(4
-chlorophenyl)-6-ethylpyrimidine (33.1.60), is synthesized from 4-chlorobenzycyanide, which upon condensation with methyl ester of propionic acid in the presence of sodium methoxide gives the β-ketonitrile (33.1.58). Reacting this with ethyl orthoformate gives a methoxymethylene derivative (33.1.59), which upon heterocyclization in pyrimidine using guanidine as the binucleophile forms the desired pyrimethamine (33.1.60).

Veterinary Drugs and Treatments

In veterinary medicine, pyrimethamine is used to treat Hepatozoon americanum infections, and toxoplasmosis in small animals (often in combination with sulfonamides). In horses, it is used to treat equine protozoal myeloencephalitis, sometimes called equine toxoplasmosis. In humans, pyrimethamine is used for the treatment of toxoplasmosis and as a prophylactic agent for malaria.

Drug interactions

Potentially hazardous interactions with other drugs Increased antifolate effect with sulphonamides, trimethoprim, methotrexate and pemetrexed. Antiepileptics: anticonvulsant effect of fosphenytoin and phenytoin antagonised, also increased antifolate effect. Antimalarials: avoid concomitant use with artemether/lumefantrine; increased antifolate effect with proguanil.

Metabolism

Pyrimethamine is metabolised in the liver and slowly excreted via the kidney, with up to 30% recovered in the urine as parent compound over a period of several weeks. Several metabolites have also been detected in the urine, although data are lacking on the nature of these metabolites, their route, rate of formation and elimination, and any pharmacological activity, particularly after prolonged daily dosing.

InChI:InChI=1/C12H13ClN4/c1-2-9-10(11(14)17-12(15)16-9)7-3-5-8(13)6-4-7/h3-6H,2H2,1H3,(H4,14,15,16,17)

Synthetic route

2,4-diamino-5-(3-azido-4-chlorophenyl)-6-ethylpyrimidine (95458-40-5) → 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0)

Conditions	Yield
With hydrazine hydrate for 0.25h; Heating;	85%

4-Chlorophenylboronic acid (1679-18-1) + 2,4-diamino-6-ethyl-5-iodopyrimidine (514854-13-8) → 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0)

Conditions	Yield
With dipotassium hydrogenphosphate; Pd(OAc)2(dppf)2 In 1,2-dimethoxyethane for 24h; Suzuki cross-coupling; Heating;	76%

5-(4-chlorophenyl)pyrimidine-2,4-diamine (17039-14-4) + Ethyl boronic acid (4433-63-0) → 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0)

Conditions	Yield
Stage #1: 5-(4-chlorophenyl)pyrimidine-2,4-diamine With acetic acid; trifluoroacetic acid In acetonitrile at 20℃; for 0.166667h; Minisci Aromatic Substitution; Green chemistry; Stage #2: Ethyl boronic acid With oxygen In acetonitrile at 110℃; under 760.051 Torr; for 10h; Minisci Aromatic Substitution; Green chemistry;	74%

C12H12ClN6(1+)*BF4(1-) → 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0)

Conditions	Yield
With formamide; triethylamine Ambient temperature;	64%

1-(4-chlorophenyl)-1-cyano-2-methoxybut-1-ene + guanidine hydrochloride (50-01-1) → 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0)

Conditions	Yield
With sodium methylate In various solvent(s) for 16h; Heating;	50%

diazomethane (186581-53-3, 908094-01-9) + α-(4-chlorophenyl)-α-propionylacetonitrile (55474-40-3) → 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0)

Conditions	Yield
With diethyl ether anschliessenden Erwaermen mit Guanidin in Aethanol;

6-ethyl-2-amino-5-(4-chloro-phenyl)-3H-pyrimidine-4-thione (105640-59-3) → 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0)

Conditions	Yield
With ethanol; ammonia at 180℃;

N-[4-ethyl-6-chloro-5-(4-chloro-phenyl)-pyrimidin-2-yl]-acetamide (100716-90-3) → 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0)

Conditions	Yield
With ethanol; ammonia at 155℃;
With ammonia; phenol at 110℃;

2-(4-chloro-phenyl)-3-isobutoxy-pent-2-enenitrile (67466-67-5) + sodium ethanolate (141-52-6) + guanidine nitrate (506-93-4) → 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0)

Conditions	Yield
With ethanol

3-anilino-2-(4-chloro-phenyl)-pent-2-enenitrile + Triethyl orthoacetate (78-39-7) → 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0)

Conditions	Yield
anschliessenden Erhitzen mit Guanidin in Aethanol auf 130grad/2 Torr;

Diacetamidopyrimethamine (71523-78-9) → 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0)

Conditions	Yield
With zinc(II) chloride In ethanol for 2h; Ambient temperature;

N-[5-(4-Chloro-phenyl)-2-(2,2-dimethyl-propionylamino)-6-ethyl-pyrimidin-4-yl]-2,2-dimethyl-propionamide (143947-40-4) → 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0)

Conditions	Yield
With zinc(II) chloride In ethanol for 2h; Heating;
Multi-step reaction with 3 steps 1: ZnCl2 / ethanol / 2 h / Heating 2: 76 percent / Heating 3: ZnCl2 / ethanol / 6 h / Heating View Scheme

C26H21ClN4O2 (143947-41-5) → 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0)

Conditions	Yield
With zinc(II) chloride In ethanol for 6h; Heating;
Multi-step reaction with 3 steps 1: ZnCl2 / ethanol / 6 h / Heating 2: 62 percent / Heating 3: ZnCl2 / ethanol / 2 h / Heating View Scheme

2-ethyl-6-chloro-5-<4-chloro-phenyl>-pyrimidin-2-ylamine → 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0)

Conditions	Yield
With ethanol; ammonia at 130℃;

sodium ethanolate (141-52-6) + <1-ethyl-2-<4-chloro-phenyl>-2-cyano-vinyl>-guanidine → 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0)

Conditions	Yield
With ethanol anschliessenden Erhitzen mit Guanidin in Aethanol auf 130grad/2 Torr;

guanidine nitrate (113-00-8) + α-(4-chlorophenyl)-β-methoxy-α-propionylacrylonitrile → 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0)

Conditions	Yield
In dimethyl sulfoxide at 80℃; for 0.0833333h;	0.70 g

6-ethylisocytosine (5734-66-7) → 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0)

Conditions	Yield
Multi-step reaction with 4 steps 1: 90 percent / POCl3 / Heating 2: 35 percent aq. NH3 3: 56 percent / I2; aq. NaOH / CHCl3 / 5 h 4: 76 percent / Pd(OAc)2(dppf)2; aq. K2HPO4 / 1,2-dimethoxy-ethane / 24 h / Heating View Scheme

2,4-diamino-6-ethylpyrimidine (514854-12-7) → 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0)

Conditions	Yield
Multi-step reaction with 2 steps 1: 56 percent / I2; aq. NaOH / CHCl3 / 5 h 2: 76 percent / Pd(OAc)2(dppf)2; aq. K2HPO4 / 1,2-dimethoxy-ethane / 24 h / Heating View Scheme

2-amino-4-chloro-6-ethylpyrimidine (5734-67-8) → 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0)

Conditions	Yield
Multi-step reaction with 3 steps 1: 35 percent aq. NH3 2: 56 percent / I2; aq. NaOH / CHCl3 / 5 h 3: 76 percent / Pd(OAc)2(dppf)2; aq. K2HPO4 / 1,2-dimethoxy-ethane / 24 h / Heating View Scheme

α-(4-chlorophenyl)-α-propionylacetonitrile (55474-40-3) → 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0)

Conditions	Yield
Multi-step reaction with 2 steps 1: dioxane / 20 °C 2: 0.70 g / dimethylsulfoxide / 0.08 h / 80 °C View Scheme
Multi-step reaction with 2 steps 1: 100 °C 2: anschliessenden Erhitzen mit Guanidin in Aethanol auf 130grad/2 Torr View Scheme
Multi-step reaction with 2 steps 1: toluene-4-sulfonic acid; toluene 2: ethanol View Scheme

p-chlorobenzyl cyanide (140-53-4) → 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0)

Conditions	Yield
Multi-step reaction with 3 steps 1.1: LDA / tetrahydrofuran / 0.17 h / -78 °C 1.2: 62 percent / tetrahydrofuran / -78 °C 2.1: dioxane / 20 °C 3.1: 0.70 g / dimethylsulfoxide / 0.08 h / 80 °C View Scheme
Multi-step reaction with 3 steps 1: sodium ethylate 2: 100 °C 3: anschliessenden Erhitzen mit Guanidin in Aethanol auf 130grad/2 Torr View Scheme
Multi-step reaction with 2 steps 1: sodium ethylate 2: diethyl ether / anschliessenden Erwaermen mit Guanidin in Aethanol View Scheme
Multi-step reaction with 4 steps 1.1: sodium ethanolate / ethanol / 4 h / 80 °C 2.1: sodium hydride / tetrahydrofuran / 1.5 h / 0 - 20 °C / Inert atmosphere 2.2: 5 h / 0 - 20 °C / Inert atmosphere 3.1: sodium ethanolate / ethanol / 10 h / 80 °C 4.1: trifluoroacetic acid; acetic acid / acetonitrile / 0.17 h / 20 °C / Green chemistry 4.2: 10 h / 110 °C / 760.05 Torr / Green chemistry View Scheme

2,4-diamino-5-<4-chloro-3-(3-methyltriazen-1-yl)phenyl>-6-ethylpyrimidine → 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0)

Conditions	Yield
Multi-step reaction with 3 steps 1: 95 percent / 0.5M aq. HCl / 0.08 h / Heating 2: 1.) NaNO2, 5M aq. HCl; 2.) NaN3 / 1.) 0 deg C; 2.) 0 deg C, 2 h 3: 85 percent / 98percent hydrazine hydrate / 0.25 h / Heating View Scheme

2,4-diamino-5-(3-amino-4-chlorophenyl)-6-ethylpyrimidine (24851-19-2) → 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0)

Conditions	Yield
Multi-step reaction with 2 steps 1: 1.) NaNO2, 5M aq. HCl; 2.) NaN3 / 1.) 0 deg C; 2.) 0 deg C, 2 h 2: 85 percent / 98percent hydrazine hydrate / 0.25 h / Heating View Scheme
Multi-step reaction with 4 steps 1: 1.) 3M aq. HCl, aq. NaNO2 / 1.) 0 deg C; 2.) 0 deg C, 2 h 2: 95 percent / 0.5M aq. HCl / 0.08 h / Heating 3: 1.) NaNO2, 5M aq. HCl; 2.) NaN3 / 1.) 0 deg C; 2.) 0 deg C, 2 h 4: 85 percent / 98percent hydrazine hydrate / 0.25 h / Heating View Scheme
Multi-step reaction with 2 steps 1: NaNO2, aq. HBF4 2: 64 percent / Et3N, formamide / Ambient temperature View Scheme

2,4-diamino-5-(4-chloro-3-nitrophenyl)-6-ethylpyrimidine (21813-35-4) → 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0)

Conditions	Yield
Multi-step reaction with 3 steps 1: SnCl2*2H2O / ethanol / Heating 2: 1.) NaNO2, 5M aq. HCl; 2.) NaN3 / 1.) 0 deg C; 2.) 0 deg C, 2 h 3: 85 percent / 98percent hydrazine hydrate / 0.25 h / Heating View Scheme
Multi-step reaction with 5 steps 1: SnCl2*2H2O / ethanol / Heating 2: 1.) 3M aq. HCl, aq. NaNO2 / 1.) 0 deg C; 2.) 0 deg C, 2 h 3: 95 percent / 0.5M aq. HCl / 0.08 h / Heating 4: 1.) NaNO2, 5M aq. HCl; 2.) NaN3 / 1.) 0 deg C; 2.) 0 deg C, 2 h 5: 85 percent / 98percent hydrazine hydrate / 0.25 h / Heating View Scheme

N-[4-ethyl-5-(4-chloro-phenyl)-6-oxo-1,6-dihydro-pyrimidin-2-yl]-acetamide (100709-69-1) → 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0)

Conditions	Yield
Multi-step reaction with 2 steps 1: trichlorophosphate 2: ammonia; phenol / 110 °C View Scheme

2-(4-chloro-phenyl)-3-oxo-propionitrile (62538-21-0) → 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0)

Conditions	Yield
Multi-step reaction with 3 steps 1.1: sodium hydride / tetrahydrofuran / 1.5 h / 0 - 20 °C / Inert atmosphere 1.2: 5 h / 0 - 20 °C / Inert atmosphere 2.1: sodium ethanolate / ethanol / 10 h / 80 °C 3.1: trifluoroacetic acid; acetic acid / acetonitrile / 0.17 h / 20 °C / Green chemistry 3.2: 10 h / 110 °C / 760.05 Torr / Green chemistry View Scheme

2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0) → 2,4-diamino-5-(4-chloro-3-nitrophenyl)-6-ethylpyrimidine (21813-35-4)

Conditions	Yield
With sulfuric acid; nitric acid at 50℃; for 1h;	95%
With sulfuric acid; nitric acid 50 deg C, 1 h; 25 deg C, 18 h;
With sulfuric acid; nitric acid

2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0) → nitropyrimethamine + 2,4-diamino-5-(4-chloro-3-nitrophenyl)-6-ethylpyrimidine (21813-35-4)

Conditions	Yield
	A n/a B 93.8%

2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0) + acetic anhydride (108-24-7) → Diacetamidopyrimethamine (71523-78-9)

Conditions	Yield
for 2h; Heating;	89%
With acetic acid for 1.5h; Heating;	57%

pentanoic anhydride (2082-59-9) + 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0) → Pentanoic acid [5-(4-chloro-phenyl)-6-ethyl-2-pentanoylamino-pyrimidin-4-yl]-amide (143947-39-1)

Conditions	Yield
Heating;	88%

6-bromo-2-phenyl-4H-benzo[2,3-d]-1,3-oxazin-4-one (66387-70-0) + 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0) → 3-[4-amino-5-(4-chloro-phenyl)-6-ethyl-pyrimidin-2-yl]-6-bromo-2-phenyl-3H-quinazolin-4-one

Conditions	Yield
In acetic acid for 6h; Heating;	84%

2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0) + propionic acid anhydride (123-62-6) → N-[5-(4-Chloro-phenyl)-6-ethyl-2-propionylamino-pyrimidin-4-yl]-propionamide (143947-37-9)

Conditions	Yield
Heating;	83%

2-methyl-6-bromo-4H-3,1-benzoxazine-4-one (19165-25-4) + 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0) → 3-[4-amino-5-(4-chloro-phenyl)-6-ethyl-pyrimidin-2-yl]-6-bromo-2-methyl-3H-quinazolin-4-one

Conditions	Yield
In acetic acid for 6h; Heating;	83%

2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0) → 4-amino-6-ethyl-1,3,5-triazin-2-yl p-chlorophenyl ketone

Conditions	Yield
With air; hematoporphyrin In ethanol for 7h; Irradiation;	81%
With air; hematoporphyrin In ethanol for 7h; Product distribution; Mechanism; Irradiation; further solvents and sensitizens;

butanoic acid anhydride (106-31-0) + 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0) → N-[2-Butyrylamino-5-(4-chloro-phenyl)-6-ethyl-pyrimidin-4-yl]-butyramide (143947-38-0)

Conditions	Yield
Heating;	77%

2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0) + benzoic acid anhydride (93-97-0) → C26H21ClN4O2 (143947-41-5)

Conditions	Yield
Heating;	76%

methanesulfonic acid (75-75-2) + 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0) → 5-(4-chlorophenyl)-6-ethyl-2,4-pyrimidinediamine methane sulfonic acid

Conditions	Yield
In acetone at 20℃; for 1h; Solvent;	70%

2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0) + 2,2-dimethylpropanoic anhydride (1538-75-6) → N-[5-(4-Chloro-phenyl)-2-(2,2-dimethyl-propionylamino)-6-ethyl-pyrimidin-4-yl]-2,2-dimethyl-propionamide (143947-40-4)

Conditions	Yield
Heating;	62%

2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0) → 2-amino-5-(p-chlorophenyl)-t-6-ethyl-5,6-dihydro-r-5-hydroxy-4(3H)-pyrimidinone

Conditions	Yield
With sodium tetrahydroborate; air; rose bengal In ethanol for 24h; Irradiation;	39%
With sodium tetrahydroborate; air; rose bengal In ethanol for 24h; Mechanism; Irradiation;

2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0) + acetic anhydride (108-24-7) → acetyl-pyrimethamine (74124-11-1) + triacetyl-pyrimethamine (74124-12-2)

Conditions	Yield
With pyridine Ambient temperature;	A 31.5% B 13%

2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0) → 2-amino-5-(4-chlorophenyl)-6-ethylpyrimidin-4(3H)-one (91396-20-2)

Conditions	Yield
With hydrogenchloride; water
With hydrogenchloride In water for 48h; Reflux; Inert atmosphere;

2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0) + acetic anhydride (108-24-7) → tetracetyl-pyrimethamine (74124-13-3)

Conditions	Yield
With pyridine Ambient temperature;

2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0) + acetyl chloride (75-36-5) → Diacetamidopyrimethamine (71523-78-9)

Conditions	Yield
With dmap In pyridine for 12h; Ambient temperature;

2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0) → 2-amino-5-(4-chlorophenyl)-6-ethylpyrimidin-4(3H)-one (91396-20-2) + 4-amino-5-(4-chlorophenyl)-6-ethylpyrimidin-2(1H)-one (93456-61-2)

Conditions	Yield
With hydrogenchloride In water for 18h; Heating;	A 33 % Spectr. B 67 % Spectr.

2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0) → 2-amino-5-(4-chlorophenyl)-6-ethylpyrimidin-4(3H)-one hydrochloride (104498-88-6) + 4-amino-5-(4-chlorophenyl)-6-ethylpyrimidin-2(1H)-one (93456-61-2)

Conditions	Yield
With hydrogenchloride In water Product distribution; boiling, 18 h; 4 deg C, 6 d; further pyrimethamine derivatives, further reagent;	A 33 % Spectr. B 7 % Spectr.

2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (58-14-0) → Phenoxy-acetic acid (E)-10-oxo-dec-5-enyl ester

Conditions	Yield
With sodium acetate; pyridinium chlorochromate In dichloromethane for 2h; Ambient temperature;

Upstream product

• 186581-53-3 diazomethane 
• 55474-40-3 α-(4-chlorophenyl)-α-propionylacetonitrile 
• 105640-59-3 6-ethyl-2-amino-5-(4-chloro-phenyl)-3H-pyrimidine-4-thione 
• 100716-90-3 N-[4-ethyl-6-chloro-5-(4-chloro-phenyl)-pyrimidin-2-yl]-acetamide 
• 67466-67-5 2-(4-chloro-phenyl)-3-isobutoxy-pent-2-enenitrile 
• 141-52-6 sodium ethanolate 
• 506-93-4 guanidine nitrate 
• 78-39-7 Triethyl orthoacetate 
• 71523-78-9 Diacetamidopyrimethamine 
• 95458-40-5 2,4-diamino-5-(3-azido-4-chlorophenyl)-6-ethylpyrimidine 
• 143947-40-4 N-[5-(4-Chloro-phenyl)-2-(2,2-dimethyl-propionylamino)-6-ethyl-pyrimidin-4-yl]-2,2-dimethyl-propionamide 
• 143947-41-5 C₂₆H₂₁ClN₄O₂ 
• 113-00-8 guanidine nitrate 
• 1679-18-1 4-Chlorophenylboronic acid 

Downstream Products

• 91396-20-2 2-amino-5-(4-chlorophenyl)-6-ethylpyrimidin-4(3H)-one 
• 143947-38-0 N-[2-Butyrylamino-5-(4-chloro-phenyl)-6-ethyl-pyrimidin-4-yl]-butyramide 
• 143947-39-1 Pentanoic acid [5-(4-chloro-phenyl)-6-ethyl-2-pentanoylamino-pyrimidin-4-yl]-amide 
• 71523-78-9 Diacetamidopyrimethamine 
• 74124-11-1 acetyl-pyrimethamine 
• 74124-12-2 triacetyl-pyrimethamine 
• 74124-13-3 tetracetyl-pyrimethamine 
• 143947-40-4 N-[5-(4-Chloro-phenyl)-2-(2,2-dimethyl-propionylamino)-6-ethyl-pyrimidin-4-yl]-2,2-dimethyl-propionamide 
• 143947-37-9 N-[5-(4-Chloro-phenyl)-6-ethyl-2-propionylamino-pyrimidin-4-yl]-propionamide 
• 143947-41-5 C₂₆H₂₁ClN₄O₂ 
• 93456-61-2 4-amino-5-(4-chlorophenyl)-6-ethylpyrimidin-2(1H)-one 
• 21813-35-4 2,4-diamino-5-(4-chloro-3-nitrophenyl)-6-ethylpyrimidine 
• 113512-19-9 2,4-diamino-6-ethyl-5-(4-methoxyphenyl)pyrimidine 
• 113494-51-2 2,4-diamino-5-(4-dimethylaminophenyl)-6-ethylpyrimidine 

Relevant articles and documents

Mechanochemical Magnesium-Mediated Minisci C-H Alkylation of Pyrimidines with Alkyl Bromides and Chlorides

A novel method to synthesize 4-alkylpyrimidines by the mechanochemical magnesium-mediated Minisci reaction of pyrimidine derivatives and alkyl halides has been reported. The reaction process operates with a broad substrate scope and excellent regioselectivity under mild conditions with no requirement of transition-metal catalysts, solvents, and inert gas protection. The practicality of this protocol has been demonstrated by the up-scale synthesis, mechanochemical product derivatization, and antimalarial drug pyrimethamine preparation.

Molecular Oxygen-Mediated Minisci-Type Radical Alkylation of Heteroarenes with Boronic Acids

The carbon-carbon bond formation via autoxidation of organoboronic acid using 1 atm of O2 is achieved in a simple, clean, and green fashion. The approach allows a technically facile and environmentally benign access to structurally diverse heteroaromatics with medicinally privileged scaffolds. The strategy also displays its practicality and sustainability in the resynthesis of marketed drugs Crestor and pyrimethamine.

Structure-based design, synthesis and preliminary evaluation of selective inhibitors of dihydrofolate reductase from Mycobacterium tuberculosis

Tuberculosis is an increasing threat, owing to the spread of AIDS and to the development of resistance of the causative organism, Mycobacterium tuberculosis, to the currently available drugs. Dihydrofolate reductase (DHFR) is an important enzyme of the folate cycle; inhibition of DHFR inhibits growth and causes cell death. The crystal structure of M. tuberculosis DHFR revealed a glycerol tightly bound close to the binding site for the substrate dihydrofolate; this glycerol-binding motif is absent from the human enzyme. A series of pyrimidine-2,4-diamines was designed with a two-carbon tether between a glycerol-mimicking triol and the 6-position of the heterocycle; these compounds also carried aryl substituents at the 5-position. These, their diastereoisomers, analogues lacking two hydroxy groups and analogues lacking the two-carbon spacing linker were synthesised by acylation of the anions derived from phenylacetonitriles with ethyl (4S,5R)-4-benzyloxymethyl-2,2-dimethyl-1,3-dioxolane-4-propanoate, ethyl (4S,5S)-4-benzyloxymethyl-2,2-dimethyl-1,3-dioxolane-4-propanoate, tetrahydrooxepin-2-one and 2,3-O-isopropylidene-d-erythronolactone, respectively, to give the corresponding α-acylphenylacetonitriles. Formation of the methyl enol ethers, condensation with guanidine and deprotection gave the pyrimidine-2,4-diamines. Preliminary assay of the abilities of these compounds to inhibit the growth of TB5 Saccharomyces cerevisiae carrying the DHFR genes from M. tuberculosis, human and yeast indicated that 5-phenyl-6-((3R,4S)-3,4,5-trihydroxypentyl)pyrimidine-2,4-diamine selectively inhibited M. tuberculosis DHFR and had little effect on the human or yeast enzymes.

Development of 2,4-diaminopyrimidines as antimalarials based on inhibition of the S108N and C59R+S108N mutants of dihydrofolate reductase from pyrimethamine resistant Plasmodium falciparum

The reduced binding of pyrimethamine to Serl08Asn (S108N) mutants of parasite dihydrofolate reductase (DHFR), which forms the basis of resistance of Plasmodium falciparum to pyrimethamine, is largely due to steric constraint imposed by the bulky side chain of N108 on Cl of the 5-p-Cl-phenyl group. This and other S108 mutants with bulky side chains all showed reduced binding to pyrimethamine and cycloguanil. Less effect on binding to some bulky mutants was observed for trimethoprim, with greater flexibility for the 5-substituent. S108N DHFR also binds poorly with other pyrimethamine derivatives with bulky groups in place of the p-Cl, and the binding was generally progressively poorer for the double (C59R+S108N) mutant. Removal of the p-Cl or replacement with m-Cl led to better binding with the mutant DHFRs. Pyrimethamine analogues with unbranched hydrophobic 6-substituents showed generally good binding with the mutant DHFRs. A number of compounds were identified with high affinities for both wild-type and mutant DHFRs, with very low to no affinity to human DHFR. Some of these compounds show good antimalarial activities against pyrimethamine-resistant P. falciparum containing the mutant DHFRs with low cytotoxicity to three mammalian cell lines.

Structural studies on bioactive compounds. Part 37. Suzuki coupling of diaminopyrimidines: A new synthesis of the antimalarial drug pyrimethamine

Suzuki reactions have been used successfully to effect cross-coupling of 5-halopyrimidines with 4-chlorobenzeneboronic acid and 2,4-diamino-5-(4-chloro-3-halo)-6-ethylpyrimidines with 4-methoxybenzeneboronic acid. The antimalarial drug pyrimethamine has been prepared by coupling 2,4-diamino-6-ethyl-5-iodopyrimidine with 4-chlorobenzeneboronic acid.

Regioselective Deacylation of 2,4-Diacylaminopyrimidine Derivatives by Lewis Acids and Crystal Structures of Two Products

Deacylation of 2,4-diacylamino derivatives of pyrimethamine and related diaminopyrimidines with tin(II) chloride or zinc chloride, in ethanol or propan-2-ol, affords 2-acyl-4-aminopyrimidines exclusively.Regioselective 4-deacylation was observed by 1H NMR spectroscopy and established by crystallographic analysis of the 2,4-dipropionylpyrimidine 11 and the corresponding 4-amino-2-propionylpyrimidine deacylation product 17.The latter exists in the solid state as an unusual base-pair dimer linked by two pairs of equivalent hydrogen bonds.

Stuctural Studies on Bio-active Compounds. Part 5. Synthesis and Properties of 2,4-Diaminopyrimidine Dihydrofolate Reductase Inhibitors bearing Lipophilic Azido Groups

A series of 2,4-diamino-5-(azidoaryl)-6-alkylpyrimidines has been prepared.The azide (36) (MZP) can be reduced by thiol reagents to the corresponding amine (28) but reductive deazidation occured when the series of azidophenyl derivatives was heated with hydrazine hydrate.Degradation of azide (36) in a trifluoroacetic acid-trifluoromethanesulphonic acid mixture at 0 deg C affords a means of introducing the bulky trifluoromethylsulphonyloxy substituent into the hindered ortho-position of the 5-aryl substituent.The products formed from thermolysis and photolysis of the azide (36) and the planar analogue 2,4-diamino-6-azidoquinazoline (70) derive from the triplet nitrene reactive intermediates. The azido compounds are potent inhibitors of rat liver dihydrofolate reductase although not as active as metoprin.The azide (36), as its ethanesulphonic acid salt, was selected for clinical trial on the basis of its ease of synthesis and suitable biological and pharmaceutical properties, and has a shorter biological half-life than compounds of comparable hydrophobicity.

Selective Reactions in the Triazene Series. Part 2. Protodediazoniation of Arenediazonium Salts with Formamide

Treatment of performed arenediazonium tetrafluoroborates or arenediazonium trifluoroacetates (formed in situ) with formamide an base effects reduction to the corresponding arene in moderate to good yield in cases where an electron-withdrawing substituent is present on the aromatic ring.Other functionalities remain unaffected.The mechanism of the protodediazoniation is shown to involve transfer of the formyl hydrogen atom to the substrate and may proceed via a 1-aryl-3-formyltriazine.

3-Imino-1,2,4-benzotriazine-1-oxides

New 3-Imino-1,2,4-benzotriazine-1-oxides of formula I SPC1 wherein R represents an alkyl, alkenyl or haloalkyl radical, a phenyl or aralkyl radical optionally substituted by alkyl, alkoxy, haloalkyl, halogen or hydroxy, X and Y each independently represent hydrogen, halogen, an alkyl or alkoxy radical, or one of the two symbols represents a phenoxy or phenylsulphonyl radical optionally substituted by halogen, alkyl, haloalkyl and/or alkoxy which are active against harmful microorganisms are disclosed.

Intermediates for the preparation of pyrimidine compounds

There is disclosed a method of making compounds represented by the formula SPC1 And which are useful as antimalarial agents. The method includes reacting a keto nitrile with a polyhydroxy compound and then reacting the product with guanidine base. In the above X is a halogen atom or a nitro group, Y is a halogen atom or hydrogen and R is hydrogen or alkyl containing 1 to 10 and preferably is lower alkyl containing 1 to 4 carbon atoms.